Clinical trial · Interventional
Daily, Encapsulated, Green Tea Extract to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain
Daily, Encapsulated, Green Tea Extract (GTE) to Mitigate Neuropathic Pain in Patients With Established Cancer-Associated Neuropathic Pain
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall objective of this study is to test an intervention of green tea extract (GTE) to mitigate neuropathic pain in patients, specifically cancer survivors, receiving supportive palliative care. The central hypothesis is that daily, oral, encapsulated GTE will mitigate neuropathic pain, as longitudinally measured by the validated Douleur Neuropathique 4 (DN4) and blood protein biomarkers reported to be linked to the development and/or chronicity of neuropathic pain.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Treatment | — | UNRESOLVED | — |
| Neuropathic Pain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Green Tea Leaf Extract Decaffeinated | Dietary Supplement | — | UNRESOLVED |
| Placebo Control | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Green Tea Extract
- interventionNames
- Dietary Supplement: Green Tea Leaf Extract Decaffeinated
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- interventionNames
- Other: Placebo Control
Primary outcomes (1)
- measure
- Change in neuropathic pain score
- timeFrame
- Baseline, end of treatment (up to 16 weeks).
- description
- Douleur Neuropathique 4 (DN4) pain questionnaire. On a scale of 0 to 10, a score of equal to or greater than 4 equals neuropathic pain.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older. * Established cancer-associated neuropathic pain. * A baseline Douler Neuropathique 4 (DN4) patient-reported neuropathic pain questionnaire score of greater than or equal to 4. * A stable pain management medication regimen, with no more than a 10% change in dosage in the past 14 days prior to enrollment. * No known allergy to rice or rice flour (basis of placebo). Exclusion Criteria: * Actively undergoing cancer treatment. * Symptoms and/or diagnosis of diabetic peripheral neuropathy. * Self-describe as consuming more than 3 cups of green tea or matcha beverages on a daily basis. * High probability of completing the study and all study-related measures/activities required by the protocol.
References
Publications (0)
Data not yet available